Cow-calf vaccinations – when it comes to immunology what makes sense and what doesn’t

Chris Chase, DVM, PhD, DACVM
Department of Veterinary and Biomedical Sciences, South Dakota State University
Brookings, SD 57007

Abstract
Vaccination is an important component for the prevention and control of disease in cattle. However, too often vaccines are viewed as a catch all solution for management and nutrition errors; the “best” vaccine can never overcome these deficiencies. Proper vaccination in the young and developing heifer is the key to long term development of that animal as a reproductive unit in the herd. Modified live vaccines (MLV) have been used because of the good antibody response, longer duration of immunity, fewer doses needed per animal and lower cost. However, non-adjuvanted MLV vaccines fail to booster well vaccinated animals as active vaccine induced immunity neutralizes vaccine virus preventing the MLV from replicating and preventing a booster immune response. Improved adjuvants have increased the scope and duration of both MLV and inactivated virus immunity. Each vaccine program needs to be based designed based on animal flow, actual “disease” threats and labor on the farm.

Key words: immunology, vaccinology, mucosal immunity

Introduction – in the beginning, there was the immune response
The immune system consists of 3 lines of defense systems: mucosa epithelium, innate immunity and adaptive or acquired immunity (Figure 1) that work together to give cattle protection from disease. The mucosa epithelium of the respiratory and gastrointestinal (GI) system is the largest immune organ of the body and provides the barrier, “the kill zone” that eliminates 99.9% of all infections (Figure 2).1 The kill zone integrates all of the components of the immune system: 1) barrier components (mucous and mucins, tight junctions); 2) innate immunity (macrophages, defensins, neutrophils, interferon, cytokines) and 3) adaptive immunity (secretory IgA and IgG, and T and B lymphocytes). This system is very susceptible to dehydration and changes in microbial populations. In addition, the mucosa epithelium along with the lamina propria is the immune “fire wall” (Figure 3),2 the immune regulatory system that provides...
Figure 2: Mucosal epithelial cells (ME) are integrated into a continuous, single cell layer that is divided into apical and basolateral regions by tight junctions. ME sense the microbiota and their metabolites to induce the production of antimicrobial peptides (AMPs). Goblet cells produce mucin and mucous, that is organized into a dense, more highly cross-linked inner proteoglycan gel that forms an adherent inner mucous layer, and a less densely cross-linked outer mucous layer. The outer layer is highly colonized by constituents of the microbiota. The inner mucous layer is largely impervious to bacterial colonization or penetration due to its high concentration of bactericidal AMPs, as well as commensals specific secretory IgA (sIgA), which is moved from their basolateral surface, where it is bound by the receptor, to the inner mucous layer. Responding to the microbiotal components, innate lymphoid cells (ILC), lymphoid tissue inducer cells (LTi) and natural killer cells (NK), produce cytokines, which stimulate AMP production and maintain the epithelial barrier.

“homeostasis” mechanisms that balance the immune system to provide a stable healthy internal environment to minimize inflammation (Figures 4A & B). Once the mucosa epithelium is breached, the innate system is the first to be activated and responds almost immediately (Figure 5). The adaptive response follows up 10-14 days later in naïve animals. The immune system is regulated to prevent an over-response (too much of a good thing). The cumulative effect of these anti-inflammatory responses is to regulate the immune system, maintain homeostasis and to direct the immune response away from the memory response to the short-term antibody immune response. At the same time, overexpression of pro-inflammatory cytokines from infectious agents, feed intake issues (acidosis, ketosis) and stress can result in immune dysfunction and an over-reactive immune system that can result in immunopathology and disease.

What? Types of vaccines and pathogens/immunogens

**MLV and inactivated – together is even better**

Modified live virus (MLV) vaccines have been used because of the good antibody response, longer duration of immunity, fewer doses needed per animal and lower cost. To lesser extent modified live bacterial vaccines have also been used (Brucella abortus, Mannheimia hemolytica Pasteurella multica, Salmonella Dublin). These ML vaccines are administered intramuscularly, intranasally or scubaneously. As the basis for establishing a good immune response, they are the best. Although the return to virulence in MLV vaccines has been minimal, mutations will occur and there is some risk of new strains arising. Non-adjuvanted MLV vaccines also fail to booster well-vaccinated animals. Active vaccine immunity neutralizes vaccine virus preventing the MLV from replicating and preventing a booster immune response. Unlike maternal interference, this active immune interference never goes away in well-vaccinated animals. The animal’s immune system can’t differentiate between a natural infection or vaccine virus. Another issue with MLV IBR (BHV-1) vaccines is that they result in latency and their continued use throughout the life of the animal will ensure that BHV-1 will be present in the herd even though the rates of shed are between the 0.13 and 2.6% of the animals shed.

Inactivated vaccines contain chemically or physically treated bacteria, toxins and/or viruses. There is no danger of replication in the vaccinated animal of the pathogen or adventitious agents that may be present in an MLV. Improved adjuvants have increased the scope and duration of inactivated virus immunity. They have several disadvantages including cost, and more doses required per animal. Inactivated vaccines generate cell-mediated responses. Interestingly there is ample evidence that inactivated vaccines can effectively boost MLV vaccines. Inactivated vaccines have also been shown to decrease BHV-1 latency shed rates.

---

**Figure 3:** (1) The mucus represents the primary barrier limiting contact between the microbiota and host tissue preventing microbial translocation. (2) Epithelial cells produce antimicrobial peptides that also play a significant role in limiting exposure to the commensal microbiota. (3) Translocating commensals are rapidly eliminated by tissue-resident macrophages. (4) Commensals or commensal antigens can also be captured by DCs that traffic to the mesenteric lymph node from the lamina propria but do not penetrate further. Presentation of commensal antigens by these DCs leads to the differentiation of commensal-specific regulatory cells (Treg), Th17 cells, and IgA-producing B cells. Commensal-specific lymphocytes traffic to the lamina propria and Peyer’s patches. In the Peyer’s patches, Treg can further promote class switching and IgA generation against commensals. The combination of the epithelial barrier, mucus layer, IgA, and DCs and T cells comprises the “mucosal firewall,” which limits the passage and exposure of commensals to the gut.

What to vaccinate for? What pathogens make sense?
Cattle vaccine programs are probably the most effective against viral pathogens (bovine herpesvirus 1 [BHV-1; IBR] bovine respiratory syncytial virus [BRSV] and bovine viral diarrhea virus [BVDV]). This is because many of the cattle bacterial pathogens (Histophilus somni, Mannheimia hemolytica, Pasteurella multica, Moraxella spp., Mycoplasma bovis, Salmonella Typhimurium, Clostridium perfringens) are “normal inhabitants” of the bovine microbiome and they are “endemic” in most herds. Stressors that are discussed below play a major role in allowing these “normal” bugs to become pathogenic. Looking at a herd it is essential to have a strong diagnostic program in place to get an accurate pathogen diagnosis. With next-generation sequencing, diagnostic PCR and good old-fashioned pathology and microbiology isolation, there has never been a better time to determine which pathogens are occurring and when.

Being strategic in vaccination requires targeting those pathogens on that farm or ranch. Another term that we have learned from COVID 19 is Replication Rate called “R naught” \( (R_0) \). Replication rate is the number of susceptible animals that 1 infected animal can infect (Figure 6). Probably one of the most “infectious” viruses is BRSV (Table 1). BRSV has been estimated to have an \( R_0 \sim 36 \). A BRSV-susceptible animal (neonate) is highly susceptible to BRSV infection because of the high \( R_0 \). In a herd with BRSV disease history, BRSV vaccination would be on the top of the list. Once an animal is infected with BRSV and is endemic, the immunity is not perfect, but \( R_0 \) is 1.1 so BRSV is barely circulating in the herd (Table 1). For IBR and BVDV transient infections, the rate is around \( \sim 3 \) meaning 1 infected animal shedding virus could potentially infect 3 susceptible animals (Table 1). By the time we get 70-80% of the animals either infected or protected from vaccination, the occurrence of infections to those viruses will be low and herd immunity has been achieved (Table 1). The BVDV PI animal is the one case that

![Figure 4: A) Commensals promote the induction of regulatory T cells via direct sensing of microbial products or metabolites by T cells or dendritic cells. Further commensals promote the induction of Th17 cells that can regulate the function and homeostasis of epithelial cells. In the context of inflammation, similar mechanisms may account for the regulatory role of the microbiota. B) Commensal-derived metabolites can also have a local and systemic effect on inflammatory cells. For example, SCFA can inhibit neutrophil activation. Upon entrance in the tissue, inflammatory monocytes can also respond to microbial-derived ligands by producing mediators such as PGE2 that limit neutrophil activation and tissue damage.](image)

totally destroys the concept of herd immunity. Since the BVDV PI animal continually sheds virus, any susceptible animal is at risk of infection. This makes the $R_0$ for a herd with BVDV PI of $\infty$ “infinity”, indicating that a herd with a PI animal can never vaccinate their way out of the threat of BVDV. Endemic viral infections frequently include rotavirus and bovine coronavirus and along with Clostridial perfringens, represent a threat to the newborn susceptible animals. Environmental pathogens like Bacillus anthracis (anthrax), Leptospira spp., E. coli, and Campylobacter require considerations based on herd history and locality. Finally, Brucella abortus represents a “regulatory” vaccine.

When do we vaccinate – age and stressors

Age

**Neonatal calves**

The newborn calf is immunological naïve at birth. It has had no chance to enhance adaptive immunity by “experience” because of the protective environment in the uterus. It is further handicapped by maternal factors and the hormonal influences of parturition, and by its lack of antibodies in circulation and in the tissues. The ingestion of colostrum is essential for providing the neonate with immunological protection during at least the first 2-4 weeks of life. While all the essential immune components are present in the neonate at birth, many of the components are not functional until the calf is at least 3 weeks of age and may continue to develop until puberty. This ongoing maturation of the immune system in the developing neonate coupled with maternal antibody interference makes vaccination strategy more complex. The mucosa epithelium provides immune function very early, making intranasal and oral vaccines effective in calves less than a week of age. Parenterally administered MLV vaccine responses begin at 7-10 days following birth, although BVDV MLV vaccines should be avoided in beef calves before at least 1 month of age as the major BVDV vaccine strains inhibit innate immune bacterial killing for 10-14 days following vaccination.  

**Calves (< 3 months)**

- Respiratory diseases
  - MLV intranasal vaccines (depends on maternal antibody levels – many MLV IM or SC are not effective before 30-45 days – only adjuvanted MLV IM or SC).
  - Branding time (30-60 days of age) – MLV IM or SC – adjuvanted; inactivated viral vaccines? Well-adjuvanted, not affected by maternal antibody?
- Enteric Disease
  - Rota-covirus MLV – 1 dose – within the first week of life – not recommended due to maternal interference and later onset of protection.
  - Clostridial perfringens toxoid in the first 3-5 days after birth.

**Weaning-puberty (arrival)**

Vaccination programs are a routine practice in beef operations to protect cattle against bovine respiratory diseases (BRD). Current vaccine protocols recommend that calves be vaccinated prior to weaning or commingling, to provide protection against BRD. Unfortunately, many calves are not vaccinated prior to weaning or commingling into backgrounding lots, feedlots or pasture operations. These animals are at increased risk of viral infection and are predisposed to secondary bacterial pneumonia. However, the highly stressed calf presents a unique problem, the vaccines may sometimes actually predispose the calves to more severe disease while on other occasions providing protection.

The time from vaccination to onset of protection can play an important role in subsequent management of newly arrived cattle against BRD viral agents i.e., bovine herpesvirus 1 (BHV-1; IBR) bovine respiratory syncytial virus (BRSV) and bovine viral diarrhea virus (BVDV). Commercially available MLV vaccines administered to non-vaccinated, low-stress calves
at weaning or at arrival to feed yards will provide increased weight gains and protection to animals as early as 48 hours prior to an IBR exposure, at 5-7 days prior to a BVDV and 8 days prior to BRSV exposure.

This protection is due to the innate immune response, which is activated within hours after exposure to modified-live vaccines or infectious virus.

**Frequency of vaccination**

No more than 1-2 doses of MLV or 2-3 doses of inactivated vaccines should be administered in young calves less than 4 months of age to develop good herd immunity against respiratory diseases.

**Interval between doses of vaccine**

In all animals following vaccination, there is expansion in the populations of responding T- and B-cells. However, to have a complete and mature immune response, this T- and B-cell expansion must not only stop, but an active process of cell death (apoptosis) must also occur. This “waning process” allows “culling” T- or B-cells that may be poor responders or even cause autoimmunity to be removed by apoptosis. This whole process from vaccination to achieving mature immune response homeostasis takes at least 3 weeks (Figure 7). This fully developed, mature primary response can then be boosted to get a true anamnestic secondary response. In many cases, cattle vaccine primary and booster doses are administered at 2-week intervals. In young calves, this is done to provide an opportunity to make sure that the calves develop a primary response in the face of maternal immunity. The adjuvants that are used with most commercial vaccines provide superior immune development over older generation adjuvants like alum. Therefore, in most instances, if primary vaccination occurs after 3 weeks of age, booster vaccination between 3 weeks and even longer will be efficacious (Figure 7). The dogma that revaccination must occur within 2 weeks of the primary vaccination is not true and the anamnestic response will be better if we wait longer.

**Table 1:** The R0 “infectivity” of common bovine viruses as compared to COVID19.

<table>
<thead>
<tr>
<th>Disease</th>
<th>R0</th>
<th>Herd immunity needed to prevent</th>
</tr>
</thead>
<tbody>
<tr>
<td>BVDV PI</td>
<td>∞</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>BRSV-naive</td>
<td>36.5*</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>BHV-1-naive</td>
<td>3.2*#^</td>
<td>75-86%</td>
</tr>
<tr>
<td>BVDV-transient</td>
<td>0.25^-3.4##</td>
<td>70-80%</td>
</tr>
<tr>
<td>BRSV-endemic</td>
<td>1.14*</td>
<td>50-60%</td>
</tr>
<tr>
<td>BHV-1-latency</td>
<td>0.5^</td>
<td>0%</td>
</tr>
<tr>
<td>COVID19</td>
<td>2-3</td>
<td>60-66%</td>
</tr>
</tbody>
</table>

^ Sarrazin S, et al. Vet J. 202, 244-249.

**Herd immunity thresholds for selected bovine vaccine-preventable diseases**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Herd immunity needed to prevent</th>
</tr>
</thead>
<tbody>
<tr>
<td>BVDV PI</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>BRSV-naive</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>BHV-1-naive</td>
<td>75-86%</td>
</tr>
<tr>
<td>BVDV-transient</td>
<td>70-80%</td>
</tr>
<tr>
<td>BRSV-endemic</td>
<td>50-60%</td>
</tr>
<tr>
<td>BHV-1-latency</td>
<td>0%</td>
</tr>
<tr>
<td>COVID19</td>
<td>60-66%</td>
</tr>
</tbody>
</table>

- **Respiratory**
  - 2-3 weeks prior to weaning
    - MLV – 1 dose
    - Inactivated – 2 doses
    - Bacterial respiratory disease?
  - At weaning
    - MLV-immune dysfunction – delay – a few days to a month
    - Inactivated – 2 doses
    - Bacterial respiratory disease?
  - 2-3 weeks post weaning
    - MLV – 1 dose
    - Inactivated – 2 doses
    - Bacterial respiratory disease?

- **Calves (> 3 months)**

  - Respiratory
    - 2-3 weeks prior to weaning
      - MLV – 1 dose
      - Inactivated – 2 doses
      - Bacterial respiratory disease?
    - At weaning
      - MLV-immune dysfunction – delay – a few days to a month
      - Inactivated – 2 doses
      - Bacterial respiratory disease?
    - 2-3 weeks post weaning
      - MLV – 1 dose
      - Inactivated – 2 doses
      - Bacterial respiratory disease?

- **Heifer development**

  - Respiratory and reproductive diseases
    - Heifers (pre-breeding)
      - Heifers need to receive at least 1 dose of MLV prior to addition to the breeding herd (one dose should contain BVDV Singer strain)
        - MLV – 2 doses – BVDV and BHV-1
        - > 6 months and 2 months before breeding
        - Inactivated viral – 2 doses
        - 5 weeks and 2 weeks before breeding
        - Leptospirosis – 2 doses
        - 5 weeks and 2 weeks before breeding
        - Brucellosis – 1 dose

---

**Figure 7:** The type of adjuvant affects the interval between the primary dose and the booster dose.

**Table 1: The R0 “infectivity” of common bovine viruses as compared to COVID19.**

**Herd immunity thresholds for selected bovine vaccine-preventable diseases**

<table>
<thead>
<tr>
<th>Disease</th>
<th>R0</th>
<th>Herd immunity needed to prevent</th>
</tr>
</thead>
<tbody>
<tr>
<td>BVDV PI</td>
<td>∞</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>BRSV-naive</td>
<td>36.5*</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>BHV-1-naive</td>
<td>3.2*#^</td>
<td>75-86%</td>
</tr>
<tr>
<td>BVDV-transient</td>
<td>0.25^-3.4##</td>
<td>70-80%</td>
</tr>
<tr>
<td>BRSV-endemic</td>
<td>1.14*</td>
<td>50-60%</td>
</tr>
<tr>
<td>BHV-1-latency</td>
<td>0.5^</td>
<td>0%</td>
</tr>
<tr>
<td>COVID19</td>
<td>2-3</td>
<td>60-66%</td>
</tr>
</tbody>
</table>

^ Sarrazin S, et al. Vet J. 202, 244-249.

**Pre-partum heifers and cows– colostrogenesis**

The prepartum animal is an excellent animal to immunize – it is a “two-fer”: respiratory and reproductive protection for the dam and colostral protection for respiratory and enteric disease for the calf. Beef cows will have better immune responses both in the prepartum and postpartum period. Some alterations in the host defense mechanisms that occur during...
the preparturient period are associated with changes in hormone profiles and the metabolic and physiological stress of parturition.

Colostrrogenesis

Colostrum synthesis in the mammary gland of the pregnant female is dependent on 2 factors: the presence of serum antibodies and a transport mechanism to move the antibody, primarily immunoglobulin G1 (IgG1), into the mammary gland. Although the pregnant cow must be immunosuppressed to maintain the allogenic fetus (otherwise the bovine fetus would be rejected), this immunosuppression appears to occur more strongly in the uterus and the placenta. This fetal protective immunosuppression does not appear to cause a high level of generalized systemic immunosuppression that affects the cow’s antibody response to vaccines or environmental antigens. However, some effect on the cell-mediated adaptive responses is observed in the pregnant animal. The movement of antibody from the circulation to the mammary gland is hormonally regulated and begins 3-4 weeks prior to calving and has its highest transport in the last 1-2 weeks of pregnancy. This coincides with increases in estrogen, decreases in progesterone and increase in the neonatal receptor (FcRn) in the mammary gland. This small window of colostrogenesis makes timing of vaccine administration to the dry cow important. Non-adjuvanted vaccines would need to be given within 4 weeks of calving to get maximum circulating levels during colostrogenesis. Adjuvanted vaccines could be given earlier in the dry-cow period, as they sustain higher antibody levels for longer periods of time. This ability to concentrate antibody ends rapidly after parturition. Colostrum from cows with premature calves will have lower levels of antibodies, so premature calves should be fed colostrum from cows that delivered full-term calves.

Respiratory and reproductive diseases (cow) and respiratory diseases (calf)

- MLV – 1 dose
  - Vaccinating pregnant cows – lower efficacy demonstrated for preventing PI in subsequent pregnancy – problems with IBR abortion in poorly vaccinated animals
  - Inactivated – 1 dose – preg check time
  - Protection shown 1 year after vaccination
- Enteric diseases for calf – rotavirus, coronavirus, C. perfringens, K99 E. coli
  - MLV – 2 doses – heifer, cows – 1 dose
  - 5 weeks and 2 weeks before calving
  - Inactivated – 2 doses – heifer, cows – 1 dose
  - 10-12 weeks and 4 weeks before calving

Postpartum heifer and cow

For the beef cow, the postpartum period is a good time for reproductive vaccination to attain the best protection for BVDV PI for the subsequent pregnancy.

Reproductive diseases – cow

- MLV and Leptospirosis – 1 dose
  - Vaccinate 45-60 days prior to breeding in beef cows to improve conception rate.
  - Inactivated – leptospirosis/(Campylobacter? non-AI) – 1 dose
  - No effect of administering inactivated vaccines prior to breeding on conception rate.

Stressors and vaccination

There is ample evidence that both physical and psychological distress can cause dysfunction of the immune function in animals, leading to an increased incidence of infectious disease. Excess heat or cold, crowding, mixing, dehydration, weaning, calving, limit-feeding, shipping, noise and restraint are stressors that are often associated with intensive animal production and have been shown to influence immune function in cattle (Figure 8). Also, social status, genetics, age and the duration of stress (chronic vs. acute) have been shown to be important in the animal’s response to stress. There is clear evidence that waiting to vaccinate at least 2 days and preferable as long as 2 weeks after the stress will result in better immunity and less sickness in that adjustment period after the stress.

How do we vaccinate – route and good nutritional plane

Mucosal delivery vs. parenteral delivery

Mucosal delivery of vaccine either orally or intranasal is a strategy that has been used for 3 reasons: 1) mucosal responses occur earlier in the neonatal calf than parenteral; 2) the presence of systemic maternal antibody has little effect on generating antigenic mass necessary for developing an immune response that occurs following immunizing with a mucosal vaccine (in the face of maternal antibody – IFOMA); and 3) mucosal vaccination results in the generation of secretory IgA that is produced locally and protects mucosal surfaces where most pathogens are colonized and/or infect the host (Figure 9).

For all vaccines, mucosal or parenteral, the critical immune reactions occur in the draining lymph node (Figure 9 and Figure 10). With the right adjuvanted parenteral MLV vaccine, a protective mucosal IgA response can occur IFOMA. The paradigm that only mucosal vaccines result in the immune response IFOMA and induce mucosal IgA is not true. However, the key ingredient for a parenteral MLV vaccine to induce mucosal immunity is the adjuvant. Most adjuvants cannot overcome IFOMA and/or produce a mucosal IgA response (Figure 10). The more sophisticated oil-saponin adjuvants have this ability.

Needleless injections

Needle-free injection device (NFID) result in a high-pressure stream that penetrates the epidermis, dermis with some subcutaneous penetration. NFID administered vaccines can use half to a tenth of the dose required for intramuscular vaccines because of the higher antigen dispersion and contact with the antigen presenting cells found in skin. The use of NFID decreases the number of needle-stick injuries. Needle-free devices also have disadvantages, including start-up cost of the equipment, exhaustible gas-storage infrastructure (for those systems using compressed or CO2 gas system), technical and operational expertise (training of the operators and maintenance of the units), and inability to completely replace needle-syringe devices. The cost of the equipment varies depending on the type of needle-free injector and there are additional associated costs with maintenance and infrastructure especially with compressed gas devices. Needle-free application requires a consistent application method. Needle-free devices are calibrated to deliver the vaccine when the needle-free device is perpendicular (90°) to the skin. Vaccinations made at more acute or oblique angles will affect the distribution of the vaccine in the tissue. In addition, because of the moving parts...
Figure 8: Immune responses are highly dynamic and are shaped by various host and environmental factors, including host genetics, mode of delivery, diet and the microbiota of the mother, environmental housing, weaning, feeding type, transportation, comingling, antibiotic treatment, vaccination, and pathogen exposure.

and gas system, regular maintenance is required. Finally, there is no “one-size-fits-all” needle-free device for all applications that require injections. Humidity, cattle breed, hide condition (hair coat, mud, snow, etc.) and age of the animal all effect the elasticity and thickness of the hide greatly changing the force required for correct delivery. Different ages, breeds of cattle, treatment dose, and viscosity of injection substance require different injection volume, injection pressure, and even different NFIDs. Adoption of needle-free devices in the U.S. cattle industry has been slow although there has been better adaption in the swine industry driven by foreign markets that require the use of NFID. Reasons for this low industry implementation rate involve cost of the unit and associated maintenance and infrastructure costs, higher complexity than needle-syringe device, availability of devices (a smaller handheld injector that is used in Europe is not available in the U.S.), uncertainty if the animal was vaccinated (i.e., no physical sensation that the animal was vaccinated and/or a “wet” appearance at the injection site) and requirement for training.

Hydration and nutrition

One of the most critical issues in poor responses to vaccines are when animals have low water and feed intakes as a result of lack of supply, transportation, etc. The immune system requires hydration and energy for the barrier to be effective and for the immune system to actively respond and develop effective an immune response quickly including duration of immunity and requirement for training.

Where does the intranasal vaccine response occur?

Figure 9: 1) Delivery of nasal vaccine; 2) Uptake of vaccine antigen through nasal mucosa; 3) Immune-induction in nasal associated lymphoid tissue (NALT) including tonsils; 4) Antigen targeting and migration of mucosal dendritic cells (DCs) to regional lymph node; 5) Immune induction and amplification in regional (cervical) lymph nodes by antigen-loaded DCs and macrophages (MΦ); 6) Compartmentalized homing and exit of NALT-induced T and B cells to secretory effector sites in airways, gut, and uterine cervix; and 7) Local production and polymeric Ig receptor (pIgR)-mediated external transport of dimeric IgA to generate secretory IgA (SigA).

Conclusions

Management of the cow’s and calf’s immune system is not a simple process. Stressors and nutrition often compromise immunity. It is important that vaccinations be given at optimal times and that vaccination is not overused. Vaccination can never overcome poor management.
References

1. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. *Nature* 2012;489(7415), 231-241. [https://doi.org/10.1038/nature11551](https://doi.org/10.1038/nature11551)

2. Belkaid Y, Hand TW. Role of the Microbiota in Immunity and Inflammation. *Cell* 2014;157(1):121-141. [https://doi.org/10.1016/j.cell.2014.03.011](https://doi.org/10.1016/j.cell.2014.03.011)


